Donald A. Bergstrom M.D., Ph.D.
Net Worth
Last updated:
What is Donald A. Bergstrom M.D., Ph.D. net worth?
The estimated net worth of Dr. Donald A. Bergstrom M.D., Ph.D. is at least $12,295,707 as of 27 Jun 2024. He owns shares worth $1,791,049 as insider, has earned $7,825,378 from insider trading and has received compensation worth at least $2,679,280 in Relay Therapeutics, Inc..
What is the salary of Donald A. Bergstrom M.D., Ph.D.?
Dr. Donald A. Bergstrom M.D., Ph.D. salary is $669,820 per year as Executive Vice President and Head of R&D in Relay Therapeutics, Inc..
How old is Donald A. Bergstrom M.D., Ph.D.?
Dr. Donald A. Bergstrom M.D., Ph.D. is 53 years old, born in 1972.
What stocks does Donald A. Bergstrom M.D., Ph.D. currently own?
As insider, Dr. Donald A. Bergstrom M.D., Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Relay Therapeutics, Inc. (RLAY) | Executive Vice President and Head of R&D | 526,779 | $3.4 | $1,791,049 |
What does Relay Therapeutics, Inc. do?
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Donald A. Bergstrom M.D., Ph.D. insider trading
Relay Therapeutics, Inc.
Dr. Donald A. Bergstrom M.D., Ph.D. has made 42 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 648 units of RLAY stock worth $4,056 on 27 Jun 2024.
The largest trade he's ever made was exercising 56,324 units of RLAY stock on 16 Apr 2021. As of 27 Jun 2024 he still owns at least 526,779 units of RLAY stock.
Relay Therapeutics key executives
Relay Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Donald A. Bergstrom M.D., Ph.D. (53) Executive Vice President and Head of R&D
- Dr. Mark Murcko Ph.D. (65) Co-Founder & Director
- Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A. (51) Chief Executive Officer, Pres & Director
- Mr. Alexis A. Borisy A.M. (53) Co-Founder & Independent Chairman
- Mr. Brian R. Adams J.D. (51) Gen. Counsel & Sec.